As of 2025-06-22, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (19.86) USD. This relative valuation is based on P/E multiples. With the latest stock price at 309.70 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -106.4%.
The range of the Relative Valuation is (21.51) - (20.31) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.9x - 9.8x | 8.4x |
| Forward P/E multiples | 10.4x - 11.3x | 10.8x |
| Fair Price | (21.51) - (20.31) | (19.86) |
| Upside | -106.9% - -106.6% | -106.4% |
| Date | P/E |
| 2025-06-18 | -150.99 |
| 2025-06-17 | -149.25 |
| 2025-06-16 | -149.28 |
| 2025-06-13 | -148.90 |
| 2025-06-12 | -147.30 |
| 2025-06-11 | -144.35 |
| 2025-06-10 | -146.23 |
| 2025-06-09 | -146.97 |
| 2025-06-06 | -145.44 |
| 2025-06-05 | -148.91 |
| 2025-06-04 | -147.61 |
| 2025-06-03 | -146.86 |
| 2025-06-02 | -147.98 |
| 2025-05-30 | -147.24 |
| 2025-05-29 | -141.61 |
| 2025-05-28 | -138.06 |
| 2025-05-27 | -140.25 |
| 2025-05-23 | -140.18 |
| 2025-05-22 | -139.72 |
| 2025-05-21 | -141.45 |
| 2025-05-20 | -141.02 |
| 2025-05-19 | -141.10 |
| 2025-05-16 | -137.94 |
| 2025-05-15 | -137.01 |
| 2025-05-14 | -129.35 |
| 2025-05-13 | -129.02 |
| 2025-05-12 | -130.63 |
| 2025-05-09 | -121.42 |
| 2025-05-08 | -124.90 |
| 2025-05-07 | -133.70 |
| 2025-05-06 | -130.44 |
| 2025-05-05 | -132.25 |
| 2025-05-02 | -125.41 |
| 2025-05-01 | -123.35 |
| 2025-04-30 | -127.27 |
| 2025-04-29 | -124.34 |
| 2025-04-28 | -123.21 |
| 2025-04-25 | -121.62 |
| 2025-04-24 | -117.29 |
| 2025-04-23 | -116.98 |
| 2025-04-22 | -114.46 |
| 2025-04-21 | -112.53 |
| 2025-04-17 | -113.40 |
| 2025-04-16 | -111.44 |
| 2025-04-15 | -111.65 |
| 2025-04-14 | -116.04 |
| 2025-04-11 | -114.95 |
| 2025-04-10 | -109.40 |
| 2025-04-09 | -117.61 |
| 2025-04-08 | -108.45 |